Showing results (881-890 of 2,445) with videos related to
Sort By:
Pageof 245
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013Mary E Charlton, Amanda R Kahl, Alissa A Greenbaum, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJeffrey Crawford, Pamela Sue Becker, James O Armitage, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic ChemotherapyCiara C O'Sullivan, Holly K Van Houten, Lindsey R Sangaralingham, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Genomic Testing in Lung Cancer: Past, Present, and FutureCéline Mascaux, Ming-Sound Tsao, Fred R HirschJournal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating MutationJuan Francisco Rodríguez-Moreno, María Apellaniz-Ruiz, Juan María Roldan-Romero, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal CancerVivek Verma, Pamela K Allen, Charles B Simone, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 4, 2018
Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade GliomaTanner M Johanns, Cole J Ferguson, Patrick M Grierson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
Point: combination versus single-agent chemotherapy: the argument for sequential single agentsAlison K Conlin, Andrew D SeidmanJournal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal womenTherese B BeversJournal of the National Comprehensive Cancer Network : JNCCN|May 2, 2009
Transplantation for hepatocellular carcinoma and cholangiocarcinomaB Daniel Campos, Jean F BothaPageof 245